Table 2. Prognostic factors of OS in r/rDLBCL and r/rTRIL patients, transplant eligible.
| total cohort (n = 82) | landmark analysis of the transplanted cohort (n = 61) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||
| Parameters | median OS (months) | P-value (log rank test) | HR | 95% CI | P-value | median PFS (months) | P-value (log rank test) | HR | 95% CI | P-value |
| Age at relapse | 1.01 | 0.99–1.04 | 0.319 | 1.01 | 0.98–1.03 | 0.635 | ||||
| Sex | 0.057 | 1.64 | 0.91–2.96 | 0.103 | 0.661 | 1.19 | 0.56–2.53 | 0.643 | ||
| Male | 28.91 | 37.98 | ||||||||
| Female | 11.89 | 23.79 | ||||||||
| saaIPI | 0.01 | 1.57 | 0.79–3.2 | 0.203 | 0.1 | 1.53 | 0.7–3.32 | 0.286 | ||
| saaIPI <2 | 96.16 | 90.22 | ||||||||
| saaIPI ≥2 | 12.78 | 14.1 | ||||||||
| TRIL | 1.4 | 0.69–2.81 | 0.35 | 0.185 | 1.72 | 0.73–4.04 | 0.213 | |||
| dnDLBCL | 30.23 | 0.089 | 37.98 | |||||||
| TRIL | 12.78 | 14 | ||||||||
| Bulky mass ≥7.5 cm | 0.001 | 1.91 | 0.95–3.83 | 0.068 | 0.072 | 1.53 | 0.61–3.83 | 0.362 | ||
| no | 36.7 | 37.98 | ||||||||
| yes | 8.44 | 5.29 | ||||||||
| Duration of first CR | 0.021 | 2.27 | 1.07–4.81 | 0.032 | 0.284 | 1.28 | 0.58–2.83 | 0.532 | ||
| <12 months* | 11.9 | 14 | ||||||||
| ≥12 months | 43.96 | 38.87 | ||||||||
| BMI | 0.022 | 0.041 | ||||||||
| noBMI | 28.91 | 66.86 | ||||||||
| posBMI | 13.54 | 14 | ||||||||
| conBMI | 14.72 | 0.017 | 2.76 | 1.43–5.31 | 0.002 | 14 | 0.025 | 2.63 | 1.19–5.79 | 0.017 |
| disBMI | 11.89 | 0.4 | 1.47 | 0.42–5.14 | 0.543 | 7.1 | 0.587 | 0.62 | 0.12–3.23 | 0.572 |
| prior Rituximab treatment | 0.315 | 0.627 | ||||||||
| no | 43.96 | 37.98 | ||||||||
| yes | 13.54 | 28.39 | ||||||||
| response to first salvage | 0.006 | <0.001 | ||||||||
| no | 9.3 | 4.34 | ||||||||
| yes | 36.7 | 38.87 | ||||||||
| undergone SCT | <0.001 | 0.313 | 0.16–0.63 | 0.001 | ||||||
| no | 7 | |||||||||
| yes | 36.7 | |||||||||
| remission status before SCT | 0.008 | 2.64 | 1.19–5.87 | 0.017 | ||||||
| CR | 82.46 | |||||||||
| ≥PR | 7.8 | |||||||||
| COO (IHC) | 0.379 | 0.78 | ||||||||
| GCB subtype | 26.89 | 28.39 | ||||||||
| nonGCB subtype | 18.86 | 25.79 | ||||||||
| p53 expression (IHC) | 0.451 | 0.191 | ||||||||
| p53 wt | 19.09 | 28.39 | ||||||||
| p53 alteration | 13.54 | 23.79 | ||||||||
Abbreviations: OS: overall survival, r/r: recurrent or refractory, DLBCL: diffuse large B-cell lymphoma, TRIL: transformed indolent lymphoma, HR: Hazard Ratio, CI: Confidence Interval, saaIPI: secondary age adjusted International Prognostic Index, dnDLBCL: de novo diffuse large B-cell lymphoma, SCT: stem cell transplantation, BMI: bone marrow infiltration, noBMI: no bone marrow infiltration, posBMI: positive bone marrow infiltration, conBMI: concordant bone marrow infiltration, disBMI: discordant bone marrow infiltration, SCT: stem cell transplantation, CR: complete remission, PR: partial remission, COO: cell of origin, IHC: immunohistochemistry, GCB: germinal center B-cell, wt: wildtype
*including patients not achieving complete response after front-line treatment.